vs

Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

COASTAL FINANCIAL CORP is the larger business by last-quarter revenue ($138.0M vs $117.7M, roughly 1.2× CareDx, Inc.). On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -5.8%). COASTAL FINANCIAL CORP produced more free cash flow last quarter ($246.1M vs $514.0K). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs -3.6%).

Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

CCB vs CDNA — Head-to-Head

Bigger by revenue
CCB
CCB
1.2× larger
CCB
$138.0M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+44.8% gap
CDNA
39.0%
-5.8%
CCB
More free cash flow
CCB
CCB
$245.6M more FCF
CCB
$246.1M
$514.0K
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
-3.6%
CCB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CCB
CCB
CDNA
CDNA
Revenue
$138.0M
$117.7M
Net Profit
$2.8M
Gross Margin
Operating Margin
12.4%
1.0%
Net Margin
2.4%
Revenue YoY
-5.8%
39.0%
Net Profit YoY
EPS (diluted)
$0.84
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCB
CCB
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$138.0M
$108.4M
Q3 25
$144.7M
$100.1M
Q2 25
$119.4M
$86.7M
Q1 25
$139.5M
$84.7M
Q4 24
$146.5M
$86.6M
Q3 24
$151.1M
$82.9M
Q2 24
$135.3M
$92.3M
Net Profit
CCB
CCB
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$-4.1M
Q3 25
$13.6M
$1.7M
Q2 25
$11.0M
$-8.6M
Q1 25
$9.7M
$-10.4M
Q4 24
$87.7M
Q3 24
$13.5M
$-10.6M
Q2 24
$11.6M
$-4.6M
Operating Margin
CCB
CCB
CDNA
CDNA
Q1 26
1.0%
Q4 25
12.4%
-5.6%
Q3 25
12.4%
-0.2%
Q2 25
12.0%
-12.8%
Q1 25
8.4%
-15.8%
Q4 24
11.7%
97.5%
Q3 24
10.8%
-16.6%
Q2 24
11.1%
-7.9%
Net Margin
CCB
CCB
CDNA
CDNA
Q1 26
2.4%
Q4 25
-3.8%
Q3 25
9.4%
1.7%
Q2 25
9.2%
-9.9%
Q1 25
7.0%
-12.2%
Q4 24
101.3%
Q3 24
8.9%
-12.8%
Q2 24
8.6%
-5.0%
EPS (diluted)
CCB
CCB
CDNA
CDNA
Q1 26
$0.05
Q4 25
$0.84
$-0.08
Q3 25
$0.88
$0.03
Q2 25
$0.71
$-0.16
Q1 25
$0.63
$-0.19
Q4 24
$0.95
$1.60
Q3 24
$0.97
$-0.20
Q2 24
$0.84
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCB
CCB
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$77.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$491.0M
Total Assets
$4.7B
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCB
CCB
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$177.2M
Q3 25
$194.2M
Q2 25
$186.3M
Q1 25
$230.9M
Q4 24
$260.7M
Q3 24
$240.9M
Q2 24
$228.9M
Total Debt
CCB
CCB
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
CCB
CCB
CDNA
CDNA
Q1 26
Q4 25
$491.0M
$303.1M
Q3 25
$475.3M
$311.1M
Q2 25
$461.7M
$327.4M
Q1 25
$449.9M
$379.3M
Q4 24
$438.7M
$378.4M
Q3 24
$331.9M
$273.2M
Q2 24
$316.7M
$264.7M
Total Assets
CCB
CCB
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$4.7B
$413.2M
Q3 25
$4.6B
$432.3M
Q2 25
$4.5B
$444.3M
Q1 25
$4.3B
$489.6M
Q4 24
$4.1B
$491.1M
Q3 24
$4.1B
$477.0M
Q2 24
$4.0B
$466.8M
Debt / Equity
CCB
CCB
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCB
CCB
CDNA
CDNA
Operating Cash FlowLast quarter
$254.6M
$4.3M
Free Cash FlowOCF − Capex
$246.1M
$514.0K
FCF MarginFCF / Revenue
178.3%
0.4%
Capex IntensityCapex / Revenue
6.1%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$436.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCB
CCB
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$254.6M
$21.4M
Q3 25
$59.0M
$37.4M
Q2 25
$66.0M
$9.9M
Q1 25
$71.7M
$-26.6M
Q4 24
$259.8M
$21.9M
Q3 24
$62.6M
$12.5M
Q2 24
$72.1M
$18.9M
Free Cash Flow
CCB
CCB
CDNA
CDNA
Q1 26
$514.0K
Q4 25
$246.1M
Q3 25
$57.4M
Q2 25
$64.0M
Q1 25
$68.9M
Q4 24
$249.9M
Q3 24
$60.2M
Q2 24
$69.5M
FCF Margin
CCB
CCB
CDNA
CDNA
Q1 26
0.4%
Q4 25
178.3%
Q3 25
39.7%
Q2 25
53.6%
Q1 25
49.4%
Q4 24
170.6%
Q3 24
39.8%
Q2 24
51.3%
Capex Intensity
CCB
CCB
CDNA
CDNA
Q1 26
Q4 25
6.1%
Q3 25
1.2%
Q2 25
1.7%
Q1 25
2.0%
Q4 24
6.8%
Q3 24
1.6%
Q2 24
1.9%
Cash Conversion
CCB
CCB
CDNA
CDNA
Q1 26
1.54×
Q4 25
Q3 25
4.34×
22.30×
Q2 25
5.99×
Q1 25
7.37×
Q4 24
0.25×
Q3 24
4.65×
Q2 24
6.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCB
CCB

Other$74.7M54%
Baa S Credit Enhancements$47.3M34%
Baa S Program Income$8.4M6%
Transaction Fees$4.9M4%
Servicing And Other Baa S Fees$1.6M1%
Baa S Fraud Enhancements$1.1M1%

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons